Abstract
The emergent coronavirus, designated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a zoonotic pathogen that has demonstrated remarkable transmissibility in the human population and is the etiological agent of a current global pandemic called COVID-191. We measured the dynamic (short-term) aerosol efficiencies of SARS-CoV-2 and compared the efficiencies with two other emerging coronaviruses, SARS-CoV (emerged in 2002) and Middle Eastern respiratory syndrome CoV (MERS-CoV; emerged starting in 2012). We also quantified the long-term persistence of SARS-CoV-2 and its ability to maintain infectivity when suspended in aerosols for up to 16 hours.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the the Office of the Chancellor at the University of Pittsburgh. Work performed at Tulane National Primate Research Center (CJR, ACF) was supported in part by the National Institutes of Health grant P51OD011104. RFG was supported by the National Institutes of Health grant number U19AI135995. UTMB work was supported by NIH grant R24AI120942. The Defense Health Program provided the funding for SARS-CoV-2 work in USAMRIID. The work at NIH-IRF was funded in part through the NIAID, Division of Intramural Research and Division of Clinical Research, Battelle Memorial Institute’s prime contract with NIAID under HHSN272200700016I and in whole or in part with Federal funds from the NIAID, NIH, DHHS, HHSN272201800013C. JKB performed this work as an employee of Battelle Memorial Institute. MGL performed this work as an employee of Lovelace Respiratory Research Institute and Laulima Government Solutions, LLC.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data can be made available for review upon request.
